Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

210 Press Releases
DateTitleCompany
14 Apr 12 More time, more lives: New authorisation to make life-saving treatment available to ischaemic stroke patients presenting within 4.5hrs after the onset of stroke symptoms Boehringer Ingelheim,
Published by
Business Wire
05 Apr 12 New Data to Show Viral Cure Rates in the Most Difficult to Treat Hepatitis C Patients Boehringer Ingelheim,
Published by
Business Wire
29 Mar 12 Pradaxa® reduced to £2.20 a day Boehringer Ingelheim
19 Mar 12 Pradaxa┬« (dabigatran etexilate) ÔÇô first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK1 Boehringer Ingelheim,
Published by
Business Wire
09 Mar 12 Boehringer Ingelheim expands capabilities in biopharmaceutical process science Boehringer Ingelheim
27 Feb 12 Free First Aid Training for Berkshire Kids Boehringer Ingelheim Limited
10 Feb 12 Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product supply Boehringer Ingelheim
27 Jan 12 Boehringer Ingelheim launches ÔÇśLean-to-ClinicÔÇÖ program for fast drug product supply Boehringer Ingelheim,
Published by
PharmiWeb.com
08 Nov 11 BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients 1,2 Boehringer Ingelheim,
Published by
Business Wire
07 Nov 11 Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment 1 Boehringer Ingelheim,
Published by
Business Wire
27 Oct 11 Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe Boehringer Ingelheim
21 Oct 11 New Boehringer Ingelheim Hepatitis C Data to Be Presented at AASLD Boehringer Ingelheim GmbH,
Published by
Business Wire
06 Oct 11 Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors Gilead Sciences Inc. and Boehringer Ingelheim,
Published by
Business Wire
27 Sep 11 BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events Boehringer Ingelheim GmbH,
Published by
Business Wire
21 Sep 11 Trajenta(linagliptin) launches in the UK for adults with type 2 diabetes mellitus Boehringer Ingelheim and Eli Lilly and Company,
Published by
PharmiWeb.com
21 Sep 11 Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD Boehringer Ingelheim,
Published by
Business Wire
16 Sep 11 New data for once-daily linagliptin show durable efficacy over two years Boehringer Ingelheim,
Published by
Business Wire
30 Aug 11 Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib* Boehringer Ingelheim,
Published by
PharmiWeb.com
29 Aug 11 Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib* Boehringer Ingelheim,
Published by
Business Wire
29 Aug 11 ÔéČ1 Million Awarded to Winning Projects Which Aim to Prevent Atrial Fibrillation-Related Stroke Boehringer Ingelheim GmbH,
Published by
Business Wire
28 Aug 11 Pradaxa® (dabigatran etexilate) 150mg bid provides consistent stroke reduction over warfarin in patients with atrial fibrillation taking antiplatelet or other concomitant therapies Boehringer Ingelheim,
Published by
Business Wire
26 Aug 11 Pradaxa® (Dabigatran Etexilate) Revolutionizes Stroke Prevention in Atrial Fibrillation Boehringer Ingelheim,
Published by
Business Wire
26 Aug 11 Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe Boehringer Ingelheim and Eli Lilly,
Published by
PharmiWeb.com
25 Aug 11 Trajenta® (linagliptin) Receives Approval for the Treatment of Type 2 Diabetes in Europe Boehringer Ingelheim,
Published by
Business Wire
15 Aug 11 ?Pradaxa® (dabigatran etexilate), the first new oral anticoagulant for stroke prevention in atrial fibrillation in over 50 years, now licensed for use in the UKi Boehringer Ingelheim,
Published by
Reynolds-MacKenzie
04 Aug 11 Breakthrough Therapy PRADAXA® (Dabigatran Etexilate) First Drug in 50 Years to Gain Approval for Stroke Prevention in Atrial Fibrillation in Europe Boehringer Ingelheim,
Published by
Business Wire
27 Jun 11 New data for linagliptin* show clinically meaningful efficacy similar to glimepiride but with fewer cardiovascular events Boehringer Ingelheim,
Published by
Business Wire
24 Jun 11 Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe Boehringer Ingelheim,
Published by
Business Wire
22 Jun 11 Global Stroke Prevention Awareness Initiative Draws Two Million Votes around the World Boehringer Ingelheim GmbH,
Published by
Business Wire
17 Jun 11 New Data Confirm Superior Blood Pressure Reductions in Diabetic Patients Treated with TWYNSTA® Compared to Amlodipine Alone Boehringer Ingelheim,
Published by
Business Wire
Advertising